The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies

Lignende værker

• A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
  af: Vannucchi, Alessandro M., et al.
  Udgivet: (2015)
• Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
  af: Verstovsek, Srdan, et al.
  Udgivet: (2017)
• Efficacy of Ruxolitinib for Myelofibrosis
  af: Santos, Fabio P S, et al.
  Udgivet: (2014)
• Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly
  af: Benjamini, Ohad, et al.
  Udgivet: (2012)
• Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I
  af: Mesa, Ruben A., et al.
  Udgivet: (2014)